ES2187519T3 - 7-halogeno-y 7beta,8beta-metano-taxoles, uso antineoplasico y composiciones farmaceuticas que los contienen. - Google Patents

7-halogeno-y 7beta,8beta-metano-taxoles, uso antineoplasico y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2187519T3
ES2187519T3 ES94903483T ES94903483T ES2187519T3 ES 2187519 T3 ES2187519 T3 ES 2187519T3 ES 94903483 T ES94903483 T ES 94903483T ES 94903483 T ES94903483 T ES 94903483T ES 2187519 T3 ES2187519 T3 ES 2187519T3
Authority
ES
Spain
Prior art keywords
cancer
antineoplasic
8beta
7beta
taxols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94903483T
Other languages
English (en)
Inventor
Jackson B Hester Jr
Roy A Johnson
Robert C Kelly
Eldon G Midy
Harvey I Skulnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27486333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2187519(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2187519T3 publication Critical patent/ES2187519T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A ANALOGOS DE 7-DEOXI-TAXOL DE FORMULA (I). LOS COMPUESTOS DE FORMULA (I) (INCLUIDAS LAS FORMULAS II Y III) SON UTILES PARA LOS MISMOS CANCERES PARA LOS CUALES EL TAXOL SE HA MOSTRADO ACTIVO, INCLUIDO CANCER DE OVARIO , CANCER DE MAMA EN HUMANOS, MELANOMA MALIGNO ASI COMO CANCER DE PULMON, CANCER GASTRICO, CANCER DE COLON, CANCER DE CABEZA Y CUELLO, Y LEUCEMIA.
ES94903483T 1992-12-15 1993-12-13 7-halogeno-y 7beta,8beta-metano-taxoles, uso antineoplasico y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2187519T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99057992A 1992-12-15 1992-12-15
US1382693A 1993-02-02 1993-02-02
US7633793A 1993-06-11 1993-06-11
US12297493A 1993-09-17 1993-09-17

Publications (1)

Publication Number Publication Date
ES2187519T3 true ES2187519T3 (es) 2003-06-16

Family

ID=27486333

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94903483T Expired - Lifetime ES2187519T3 (es) 1992-12-15 1993-12-13 7-halogeno-y 7beta,8beta-metano-taxoles, uso antineoplasico y composiciones farmaceuticas que los contienen.

Country Status (26)

Country Link
US (1) US6911549B1 (es)
EP (1) EP0674630B1 (es)
JP (1) JP3441458B2 (es)
KR (1) KR100317015B1 (es)
CN (2) CN1062561C (es)
AT (1) ATE226576T1 (es)
AU (1) AU687027B2 (es)
CA (1) CA2149021A1 (es)
CZ (1) CZ291177B6 (es)
DE (1) DE69332438T2 (es)
DK (1) DK0674630T3 (es)
ES (1) ES2187519T3 (es)
FI (1) FI111633B (es)
HU (1) HUT74447A (es)
IL (1) IL107950A (es)
LV (1) LV13023B (es)
MX (1) MX9307777A (es)
MY (1) MY116473A (es)
NO (1) NO313801B1 (es)
NZ (1) NZ259196A (es)
PL (1) PL185042B1 (es)
PT (1) PT674630E (es)
RU (1) RU2125996C1 (es)
SK (1) SK281897B6 (es)
TW (1) TW389758B (es)
WO (1) WO1994013655A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710287A (en) 1991-09-23 1998-01-20 Florida State University Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
US5998656A (en) * 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5814658A (en) 1992-12-09 1998-09-29 Rhone-Poulenc Rorer S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US5973160A (en) 1992-12-23 1999-10-26 Poss; Michael A. Methods for the preparation of novel sidechain-bearing taxanes
FR2712288B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9409131D0 (en) * 1994-05-09 1994-06-29 Erba Carlo Spa Unsaturated taxane compounds
FR2726272B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0738266A1 (en) * 1994-11-04 1996-10-23 PHARMACIA S.p.A. Taxane derivatives
IT1275936B1 (it) * 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
FR2732342B1 (fr) * 1995-04-03 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
US5773464A (en) * 1996-09-30 1998-06-30 Bristol-Myers Squibb Company C-10 epoxy taxanes
AU4768797A (en) 1996-10-24 1998-05-15 Institute Armand-Frappier A family of canadensol taxanes, the semi-synthetic preparation and therapeutic use thereof
US6017935A (en) * 1997-04-24 2000-01-25 Bristol-Myers Squibb Company 7-sulfur substituted paclitaxels
US7288665B1 (en) * 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US6156789A (en) * 1998-03-17 2000-12-05 Rhone-Poulenc Rorer S.A. Method for treating abnormal cell proliferation in the brain
EP1175414A1 (en) * 2000-02-02 2002-01-30 Florida State University Research Foundation, Inc. Taxane formulations having improved solubility
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
HK1047934A1 (zh) 2000-02-02 2003-03-14 佛罗里达州立大学研究基金有限公司 用作抗肿瘤剂的c7碳酸酯取代的紫杉烷
PL350028A1 (en) 2000-02-02 2002-10-21 Univ Florida State Res Found C10 carbonate substituted taxanes as antitumor agents
JP2004525860A (ja) 2000-09-22 2004-08-26 ブリストル−マイヤーズ スクイブ カンパニー 併用化学療法剤の毒性を低下させる方法
CA2354478A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 carbonate substituted taxanes
SG125888A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C10 carbonate substituted taxanes
AU2003273671A1 (en) * 2002-10-09 2004-05-04 Phytogen Life Sciences, Inc. Novel taxanes and methods related to use and preparation thereof
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
SV2006002010A (es) 2004-02-13 2006-08-23 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
EP3345631A1 (en) * 2005-02-18 2018-07-11 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
AU2012202903B2 (en) * 2005-02-18 2014-12-11 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
CA2688344C (en) 2007-05-29 2019-09-03 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN101835769A (zh) * 2007-08-22 2010-09-15 6570763加拿大有限公司 将9-二氢-13-乙酰基浆果赤霉素ⅲ转化为多烯紫杉醇或太平洋紫杉醇的方法
EP2080764B1 (en) 2008-01-18 2012-08-22 INDENA S.p.A. Solid forms of ortataxel
EP2276755A4 (en) 2008-03-31 2011-05-04 Univ Florida State Res Found C (10) -ETHYESTER- AND C (10) -CYCLOPROPYLESTER-SUBSTITUTED TAXANES
KR101014438B1 (ko) * 2008-09-26 2011-02-14 동아제약주식회사 탁산 유도체의 제조방법
CN101648973B (zh) * 2009-09-03 2012-05-30 漆又毛 水溶性紫杉烷及制备方法
EP2588490B1 (en) 2010-07-02 2017-02-22 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US8791279B2 (en) * 2010-12-13 2014-07-29 Yung Shin Pharm. Ind. Co., Ltd. Process for preparing taxoids from baccatin derivatives using lewis acid catalyst
WO2013063504A1 (en) 2011-10-26 2013-05-02 H. Lee Moffitt Cancer Center & Research Institute, Inc. Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CN111138386A (zh) * 2019-12-30 2020-05-12 重庆市碚圣医药科技股份有限公司 一种多西他赛的半合成方法
CN111763179A (zh) * 2020-07-08 2020-10-13 云南汉德生物技术有限公司 一种紫杉醇侧链的合成方法
CN115260130A (zh) * 2022-07-07 2022-11-01 上海卓鼎生物技术有限公司 一种10-脱乙酰基紫杉醇的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5157049A (en) 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629818B1 (fr) 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
FR2629819B1 (fr) 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
AU619125B2 (en) 1989-06-09 1992-01-16 Dow Chemical Company, The Process for preparing a polymer having perfluorocyclobutane rings and polymers containing perfluorocyclobutane rings
CA2023645C (fr) 1989-08-23 2002-03-26 Jean-Noel Denis Procede pour la preparation enantioselective de derives de la phenylisoserine
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
FR2658513B1 (fr) 1990-02-21 1994-02-04 Rhone Poulenc Sante Procede de preparation de l'acide cis-beta-phenylglycidique-(2r,3r).
FR2658510B1 (fr) 1990-02-21 1992-04-30 Rhone Poulenc Sante Nouveau derive de la beta-phenylisoserine, sa preparation et son emploi.
FR2662440B1 (fr) 1990-05-22 1992-07-31 Rhone Poulenc Sante Procede de preparation stereoselective de derives de la phenylisoserine.
FR2662441B1 (fr) 1990-05-22 1992-10-23 Rhone Poulenc Sante Procede de preparation enantioselective de derives de la phenylisoserine.
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5250683A (en) 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
FR2687151B1 (fr) 1992-02-07 1994-03-25 Rhone Poulenc Rorer Sa Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
DE69333339T2 (de) 1992-07-01 2004-09-23 Bristol-Myers Squibb Co. 7,8-Zyclopropataxane mit Antitumorwirkung
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2696459B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696460B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2697522B1 (fr) 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
US5380751A (en) 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
CA2109861C (en) 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
MY116473A (en) 2004-02-28
RU2125996C1 (ru) 1999-02-10
EP0674630B1 (en) 2002-10-23
NZ259196A (en) 1998-08-26
US6911549B1 (en) 2005-06-28
FI111633B (fi) 2003-08-29
LV13023B (en) 2003-12-20
CZ143795A3 (en) 1995-11-15
EP0674630A1 (en) 1995-10-04
RU95114377A (ru) 1997-06-10
PL185042B1 (pl) 2003-02-28
JP3441458B2 (ja) 2003-09-02
NO313801B1 (no) 2002-12-02
IL107950A (en) 2001-04-30
FI952920A0 (fi) 1995-06-14
JPH08506568A (ja) 1996-07-16
KR950704288A (ko) 1995-11-17
SK281897B6 (sk) 2001-09-11
DK0674630T3 (da) 2003-02-24
HU9501733D0 (en) 1995-08-28
TW389758B (en) 2000-05-11
ATE226576T1 (de) 2002-11-15
NO952351L (no) 1995-08-14
PL309392A1 (en) 1995-10-02
HUT74447A (en) 1996-12-30
SK78895A3 (en) 1995-12-06
AU5741194A (en) 1994-07-04
AU687027B2 (en) 1998-02-19
MX9307777A (es) 1994-07-29
KR100317015B1 (ko) 2002-06-22
DE69332438T2 (de) 2003-06-18
IL107950A0 (en) 1994-04-12
CN1062561C (zh) 2001-02-28
FI952920L (fi) 1995-06-14
CN1261072A (zh) 2000-07-26
CN1095377A (zh) 1994-11-23
DE69332438D1 (de) 2002-11-28
NO952351D0 (no) 1995-06-14
CZ291177B6 (cs) 2003-01-15
WO1994013655A1 (en) 1994-06-23
PT674630E (pt) 2003-03-31
CA2149021A1 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
MX9307777A (es) 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ES2123996T3 (es) Analogos de 7-etertaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
ES2181766T3 (es) Analogos de delda 12,13-isotaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
PA8494101A1 (es) Derivados heterociclicos utiles como agentes anticancerosos
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8551001A1 (es) Nuevos compuestos
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
AR023363A1 (es) Compuestos derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina, composicion y uso de los mismos
ES2124884T3 (es) Nuevos derivados de prednisolona.
ES2086313T3 (es) Nuevos derivados de xantina con efecto antagonista de adenosina.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
PY0111330A (es) Derivados de tiofeno utiles como agentes anticancerosos
CL2004001623A1 (es) Compuestos derivados de 7-(sustituido)-9-(amino sustituido)-6-desmetil-6-desoxitetraciclinas, sus sales y complejos metalicos; composicion farmaceutica y veterinaria, utiles como antibioticos.
GT200000014A (es) Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
AR028948A1 (es) Compuestos novedosos
UY26872A1 (es) Derivados de la 4- fenil piridina
PA8527001A1 (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos
UY27551A1 (es) Derivados de benzotiazol
UY28700A1 (es) Compuestos
PA8495101A1 (es) Derivados de 13-metileritromicina
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.